Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The adrenergic alpha2C receptor (ADRA2C) is a G protein-coupled receptor (GPCR) that plays a key role in regulating neurotransmitter release from sympathetic nerves and central nervous system adrenergic neurons. It is primarily involved in the inhibition of adenylate cyclase, leading to decreased cAMP levels within cells. The alpha 2C subtype modulates neurotransmission at lower levels of nerve activity due to its higher affinity for norepinephrine and slower deactivation kinetics. High expression or altered function has been associated with pathogenesis such as preeclampsia and fetal growth restriction. Its broad CNS distribution suggests roles at multiple brain levels relevant for neuropsychiatric research.
Agonist or antagonist binding to the receptor, modulating downstream signaling pathways such as adenylate cyclase inhibition via Gi/o proteins.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adrenergic alpha₂-C receptor (None).